Nevertheless, the anti-CD19 CAR-T cell approach may only be effective for SLE driven primarily by B cells and plasmablasts, whereas its therapeutic benefit is limited in autoimmune conditions mediated by plasma cells or T cells, both of which lack CD19 expression. Here, CD19 is linked to systemic lupus erythematosus.